GlassScriptPhysician profile
James J Weidel
NPI 1073790564
$2,969.55
in general payments reported to CMS, 2019-2025
17 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $51.54 · 2023: $345 · 2024: $597 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.36 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $703.64 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $392.49 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $249.42 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $241.58 | 2025 | Cobenfy |
| Alkermes, INC. | $234.19 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $232.95 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $189.00 | 2021 | |
| Axsome Therapeutics, INC. | $169.42 | 2024-2025 | Auvelity |
| Corium, LLC | $162.80 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $151.60 | 2023-2025 | Qelbree, Qelbree |
| Braeburn INC. | $62.69 | 2024-2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $59.38 | 2024 | |
| Janssen Pharmaceuticals, INC | $29.79 | 2025 | Spravato, Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $27.81 | 2021 | |
| Lundbeck LLC | $26.23 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $18.45 | 2025 | Sublocade |
| Orexo US, INC. | $18.11 | 2023 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Weidel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.